Pennsylvania Archives - Green Market Report

Debra BorchardtFebruary 7, 2022
vape.jpg?fit=960%2C668&ssl=1

3min8160

It seems Pennsylvania’s medical marijuana program has pulled flavored vapes. Last week, On February 2, 2022, the Pennsylvania Department of Health (DOH) posted a list of known additives that it says were not approved by the FDA (Food & Drug Administration) for inhalation. Then on Friday February 4, 2022, the Pennsylvania DOH issued a withdrawal of these products by many of the leading cannabis companies in the state. The products mostly seem to include flavors like citrus, candies and cookies.

The DOH sent a letter to patients and caregivers on February 4th saying that some of the additives were approved by the FDA in  non-inhalable products, but were not approved for inhalable products. They issued a mandatory recall for all the products.

The companies included on the list were:

  • AES Compassionate Care
  • Agri-Kind
  • CannTech PA
  • Cresco Labs
  • Curaleaf (OTC: CURLF)
  • FarmaceuticalRX
  • Franklin Labs
  • Greenleaf Medical
  • Goodblend Pennsylvania
  • GTI Pennsylvania (OTC: GTBIF)
  • Holistic Farms
  • Ilera Healthcare
  • Insa
  • MLH Explorations
  • Pennsylvania Medical Solutions
  • PennAlt Organics
  • PurePenn

One company not on the list was Tilt Holdings (OTC: TLLTF), which wasted no time in letting the market know it wasn’t included.

“We have always been intently focused on manufacturing products that are safe, consistent, and effective for our patients,” said CEO Gary Santo. “While we do not have enough information available to comment on the DOH’s stance with respect to the use of certain additives, we want to make it clear to our patients, investors and other stakeholders that none of our products were named in the recall. TILT will continue to support our brand partners and other cannabis operators as the regulated industry seeks a resolution that prioritizes product conformance to the new additive restrictions released by the Pennsylvania DOH on Friday.”

Pittsburgh Business Times reported that since 2018, “There have been $2.8 billion in total sales, including $1.1 billion from growers and producers to dispensaries and $1.7 billion from the dispensaries to more than 582,000 registered patients and caregivers.”

 


StaffSeptember 1, 2021
Pennsylvania.jpg?fit=960%2C640&ssl=1

3min12850

Ayr Wellness Inc. (OTCQX: AYRWF) is buying Pennsylvania-based PA Natural Medicine, LLC, which operates three licensed retail dispensaries in the Commonwealth of Pennsylvania. The deal is valued at $80 million but could see an extra $40 million if milestones are met. The deal is expected to close in the fourth quarter and Ayr said that it expects to rebrand the stores once the transaction is complete.

“Our goal across our footprint is to develop scale and meaningful presence in each of our markets. Today’s announcement builds on our already strong position in Pennsylvania, where we have built a tremendous foundation since entering the state just a few months ago. Our three Ayr Wellness stores, open an average of less than six months, are run-rating at over $7 million in annualized revenue per dispensary and our cultivation facilities are producing some of the best reviewed flower in the state,” said Jonathan Sandelman, Ayr Wellness Founder, Chairman and CEO.

PA Naturals has locations in the college towns of Bloomsburg and State College, as well as Selinsgrove, PA, and operates under the retail banner “Nature’s Medicine”. The terms of the transaction include upfront consideration of $80 million, made up of $20 million in stock, $25 million in seller notes, and $35 million in cash. An earn-out of up to $40 million, based on 2021 EBITDA hurdles, is payable in Q1 2022 and includes a maximum additional cash payment of $10 million with the remainder paid in stock and notes.

In 2018, PA Natural Medicine was described as a partnership between Nature’s Medicine, a medical marijuana company based in Arizona, and two Pennsylvania businessmen, Tony DePaul and Austin Meehan. As of June 3, the Pennsylvania Department of Health reported that 548,468 patients were registered with 349,272 active certifications.

“With such great momentum in this market, we are expanding our retail presence with the acquisition of PA Naturals, a three-store operation in central Pennsylvania with some of the best operating metrics in the state and a complementary footprint to our existing six licenses. We look forward to welcoming the great people of PA Naturals to the Ayr team,” he concluded.

Ayr Wellness said in August that it expects revenues to be approximately $800 million in 2022 and adjustedEBITDA at $300 million. The revenue estimate increased from $725 million to reflect contributions from recent acquisitions and additional expansion (including into Illinois). No doubt with this additional acquisition, the numbers could rise again.


StaffApril 27, 2021
Pennsylvania.jpg?fit=960%2C640&ssl=1

4min54060

Pennsylvania has only legalized medical marijuana, but the numbers make it look as if it is adult use cannabis driving the sales. Cannabis data company Headset recently expanded its reach into Pennsylvania and published its first full market report based on consumer insights and real-time market data. The report found that over the past twelve months, Pennsylvania’s medical cannabis sales have escalated, and between April 2020 and March 2021Pennsylvania’s medical markets brought in $909.4 million. Medical sales grew 120% in the first quarter of 2021 to $267.8 million from last year’s $121.5 million for the same time period.

The report also determined that Pennsylvania stands out among other U.S. markets with the largest average basket sizes so far this year, at $123.88 per basket. In addition, Pennsylvania’s average basket size was 2x as high as Michigan’s and 1.5x as high as Oregon’s.

“With close to $1B in sales in the last 12 months and growing at an incredible pace, we are thrilled to bring unprecedented insight into this exciting market, ” said Cy Scott, Founder and CEO of Headset. “As cannabis operators continue to make significant investments into Pennsylvania having access to extensive analysis, forecasts and a comprehensive understanding of this complex market as it continues to grow will be critical to success.”

Provided by Headset

Flower Is The Winner

Like most cannabis consumers, flower is the form factor of choice – despite being medical patients. It is even growing in market share. Flower was 38% of the market in March 2020 and is now 45% as of march 2021. Vape pens have dropped in market share, but still remain in second place taking 35% of the market. Concentrates had the highest average item price at $61, and tinctures, flower and vapor pens followed closely behind with an average item price of more than $50.

Legalization Outlook

Pennsylvania is the 5th largest state by population and is expected to be a big market with rapid growth. A new survey from Muhlenberg College’s annual public health poll found residents want full legalization.

“The trend on public support for legalization of marijuana in Pennsylvania is clear, with support growing for the eighth year in a row,” Chris Borick, director of the college’s Institute of Public Opinion, said in a statement accompanying the survey results. “As the state government considers this policy option, the public is increasingly coming to the conclusion that they support legalization.” A record level (58%) of adult Pennsylvanians support the legalization of marijuana in the Commonwealth, marking the 8th consecutive wave of this survey that support for legalization has increased in the state.

 


Debra BorchardtNovember 23, 2020
Jushi-Worker-Working-w_-Products-in-Scranton-Facility--scaled.jpg?fit=1200%2C800&ssl=1

9min23500

Jushi Holdings Inc.  (OTCMKTS: JUSHF) said it is planning a $50 million expansion project in Scranton, Pennsylvania which is expected to create more than 100 more new jobs in the Scranton area. The company said it plans to nearly double the square footage of its subsidiary’s grower-processor facility from approximately 90,000 sq. ft. to more than 160,000 sq. ft. in a phased expansion.

In 2019, the company opened the medical marijuana dispensary BEYOND / HELLO Scranton. Jushi already employs 70 people in the Scranton area and once this expansion is completed, it will have added 17 new jobs to the region. For the expansion, the company also plans to hire all local construction, electricians, and vendors for its expansion efforts.

“The medical cannabis market in Pennsylvania is rapidly growing and with our products in high-demand, this investment will significantly expand our cultivation capacity and market share,” said Jim Cacioppo, Chief Executive Officer, Chairman, and Founder of Jushi. “This is a robust operating environment and with the market intelligence gained through our eight currently operating BEYOND / HELLO retail dispensaries, we believe that patient demand for high-quality, medical-grade cannabis products is still far from being satisfied. We are very excited by the opportunity ahead of us in Pennsylvania, and as one of the fastest-growing jobs sectors in the U.S., Jushi and its subsidiaries look forward to bringing additional new local jobs and tax dollars to the region and further investing in Scranton’s economy and community.”

Pennsylvania

Pennsylvania’s Republican legislature continues to block the adult-use legalization measure despite the state’s widening budget gap.  PA Governor Tom Wolf has been pushing for the legalization of cannabis for adults and looking for ways to close the budget gaps. If adult-use legalization were to pass in PA, the cannabis industry would likely double to triple in size, which would only create more taxes for state and local coffers and jobs in PA. The state is also facing pressure from its border with New Jersey which is planning on fast-tracking the legalization of adult-use cannabis. This could negatively impact the medical market in the state.

Expansion Plans

Jushi said that the majority of the approximate 70,000 sq. ft. expansion project will be focused on increasing the facility’s canopy space, which upon completion will nearly triple to approximately 98,000 sq. ft. In a statement, the company said that the first phase of the expansion is expected to come online in mid-2021 and the final phase will be completed by the second quarter of 2022. In total, Jushi expects to invest approximately $50 million in the expansion project, which is expected to create more than 100 new jobs in the Scranton area. Jushi (through its subsidiary Pennsylvania Medical Solutions, LLC), will work with Innovative Industrial Properties Inc. (NYSE: IIPR)  (through its subsidiary IIP-PA 1 LLC) to partially finance the expansion project via an upsize to the existing lease agreement between the parties. The expansion project is subject to the company’s successful completion of certain milestones, including receipt of all local and state approvals and permits, and the finalization of a mutually agreed lease amendment with Innovative Industrial Properties Inc. related to the Facility.

The company reminded investors that it recently completed an expansion project in the third quarter of 2020, which included increasing the facility’s indoor cultivation from approximately 20,000 sq. ft. to approximately 45,000 sq. ft. (~33,000 sq. ft. of canopy) and supplementing the current CO2 extraction with new Class I, Division 1 ethanol extraction technology. The facility produces high-quality, indoor-grown flower and extracts and is strategically located within minutes of Interstate 81, Interstate 84 and the Pennsylvania Turnpike, enabling efficient wholesale distribution to the 98 dispensaries currently operating across the commonwealth, including the Company’s eight operational BEYOND / HELLO dispensaries. The facility is expected to supply the company’s subsidiaries and other licensed retail facilities.


Gretchen GaileySeptember 2, 2020
shutterstock_618227249.jpg?fit=960%2C693&ssl=1

4min26110

Editors Note: This is an opinion piece.

I would like to say kudos to Pennsylvania Governor Tom Wolf for finally calling on the Pennsylvania General Assembly to legalize adult-use cannabis. It would have been better if he had actually thought through what he was proposing and meant it.

Last week, the governor said that he would like to legalize cannabis in order to bring in more revenue for the state and he thinks that selling cannabis in the state liquor stores is the way to do it.

“My hope is that with the pandemic and the hit that we have taken to revenues that there might be a little more interest in it now. And I think that we have had a little more time to see what’s happening in places like Colorado with revenues for example. This might be one way to plug a hole….We have a state store system that would be an ideal way to distribute it,” said Wolf.

Wolf spoke about how he would like funds left over from the CARES Act and tax revenue from cannabis sales to help turn the tide of the pandemic induced recession that has hit the commonwealth, but Senator Daylin Leach the sponsor of SB350 known as the “gold standard” for adult use legalization calls the governor’s plan a nightmare.

“I think it would be unresponsive to the consumer, a bureaucratic nightmare, discourage innovation and kill large parts of the industry right off the bat. Sure, we could do it. We could do it in a way that is less profitable, less advantageous, we can do it in a way that is lesser all around. I don’t know why we would do this,” said Leach.

Wolf’s proposal would make Pennsylvania the only state-run cannabis market in the country and we all know how well things go when the government takes over. If the state runs cannabis sales, it eliminates the retail market opportunity, a key driver of market competition, which means consumers will be the ones taking the hit in their pocketbooks. It will also constrain the product market, keeping out the smaller less capitalized brands, less flexibility in what brands will be sold and less chance of innovation.

Leach says that the governor’s plan is a political nonstarter and his state store announcement did more damage than good.

“He has made it (legalization) far less likely to pass. Republicans hate the state system, they are looking to shut down the state system, not expand their portfolio. Other than sign medical, he did nothing to help us pass medical. Wolf’s efforts to pass legalization have been clumsy and ham-handed enough.”

Knowing that Republicans are opposed, and every other state has passed on a government takeover of their cannabis markets, doesn’t it seem obvious that his proposal is a poison pill? Does it not seem intentionally designed to fail? There is plenty of precedents that makes it clear from every state why no government in its right mind would take this approach.


StaffJuly 29, 2020
Patient.jpg?fit=960%2C640&ssl=1

4min31540

A new study is being conducted to measure the quality of life that medical cannabis patients in Pennsylvania report when using cannabis to address pain relief.  The University of the Sciences and Releaf App have partnered with the Pennsylvania dispensary Keystone Canna Remedies to conduct a second collaborative research study on the effectiveness of Pennsylvania’s medical cannabis program.

An original study by that group found that cannabis products with THC gave the greatest symptom relief in patients. The report said that on a 10-point scale, the pain relief seen in patients taking primarily THC products was nearly two points, a statistically significant difference from one point reduction seen in patients taking primarily CBD based products.

Dr. Andrew Peterson, Executive Director of the Substance Use Disorders Institute, and principal investigator notes that “the results of the first study showed that THC products used by PA patients had a beneficial effect on pain, but now we need to find out if a patient’s health-related quality of life is also improved as a result of the pain relief from cannabis use.”

“KCR has always prioritized the furthering of cannabis research in Pennsylvania, and dispensaries with established patient bases should be looked at as data-rich resources,” said Victor Guadagnino, Founder of Keystone Canna Remedies. “As part of our ongoing care, we equip our robust patient base with tools to self analyze which should prove very effective for this study.  Participation in this study also empowers patients to have an active role in their healthcare while engaging in a way that can shape the overall understanding of cannabis beyond state lines.”

“While Pennsylvania has a robust clinical research program designed specifically for pre-approved licensed operators and universities, one of our goals is to open up research opportunities beyond the pre-approved stakeholders to a wider group of universities, dispensaries, and cannabis brands who are commonly motivated to contribute to our growing body of cannabis research,” says Keenan Keeling, CEO of MoreBetter Ltd, the company behind Releaf App. “Focusing on the efficacy of Pennsylvania products, as reported by Pennsylvania patients, allows us to provide actionable insights to cannabis patients and regional stakeholders. Ultimately, we aim to improve the experience for both patients and healthcare professionals within the state.”

Certified medical cannabis patients in Pennsylvania medicating for pain relief who are interested in signing up to participate in this research study can reach out to medicalcannabis@usciences.edu. Healthcare professionals, dispensaries, and growers/processors in Pennsylvania who are interested in supporting or participating in this research study, or future study efforts, can reach out to tyler@releafapp.com.


StaffJune 22, 2020
Gleaf.jpg?fit=960%2C960&ssl=1

4min23900

Innovative Industrial Properties, Inc. (NYSE: IIPR) is making available $30 million for additional expansion of their cannabis cultivation and processing facilities at the Green Leaf Medical property in Saxton, Pennsylvania. The company’s lease was amended to reflect the new investment as well as an adjustment to the base rent to take into account the additional available funding and extended the term of the lease agreement. Assuming full payment of the additional funding, IIP’s total investment in the property will be $43.0 million.

“We are thrilled to expand our real estate partnership once again with Green Leaf, providing them the capital for this key expansion at their mission-critical facility in Saxton,” said Paul Smithers, President and Chief Executive Officer of IIP. “Green Leaf has always taken a thoughtful, long-term view toward expansion, and this second phase is expected to dramatically increase production capacity at the Saxton facility, with an eye toward meeting demand in one of the strongest medical cannabis markets in the United States.”

Green Leaf, which is known for its brand gLeaf, operates medical cannabis cultivation, extraction and retail operations in four contiguous states in the mid-Atlantic region, including Maryland, Pennsylvania, Ohio and Virginia, with pending vertical applications in New Jersey and West Virginia. According to Green Leaf, the company has raised approximately $27 million from the sale of equity to build its multi-state operation and has generated positive EBITDA since 2018.

In April of this year, Green Leaf announced a new debt financing transaction with Chicago Atlantic Group, raising $10 million to fund the acquisition of additional dispensaries in Virginia and Pennsylvania. Green Leaf has one of 25 medical cannabis cultivation/processor licenses issued by the state of Pennsylvania.

“We appreciate the continued strong support of IIP as our long-term real estate capital partner, and look forward to expanding capacity at our Saxton facility, which provides the enhanced infrastructure elements that are key to growing the highest quality, consistent cannabis products for our patients,” said Philip Goldberg, Chief Executive Officer of Green Leaf.

Innovative Acquired Property in 2019

IIP bought the property in a sale-leaseback transaction with Green Leaf in May of last year, which comprises two buildings totaling approximately 266,000 square feet of industrial space. Green Leaf previously redeveloped approximately 103,000 square feet of the industrial space for medical-use cannabis cultivation and processing, and this funding is expected to include the build-out of the remaining 163,000 square feet of industrial space.

IIP also owns and leases to Green Leaf an 82,000 square foot medical-use cannabis cultivation, processing, and dispensing facility in Richmond, Virginia, which the company acquired earlier this year.

Pennsylvania

With first sales in 2018, the Pennsylvania medical cannabis market has grown significantly with sales hitting $524 million. The Pennsylvania Department of Health’s report dated May 15, 2020, noted that over 300,000 patient certifications have been issued by approved practitioners since the program began.

Similar to other states, Pennsylvania has expanded its program over time, adding several new medical conditions eligible for treatment with medical cannabis, including, among others, anxiety disorders and Tourette Syndrome. In addition, according to an April 2020 study by Harper Polling, over 60% of Pennsylvanians support legalizing adult-use cannabis in the state, with strong levels of support throughout the political spectrum. Multiple bills to legalize adult-use cannabis are pending in Pennsylvania’s legislature.


Debra BorchardtJune 22, 2020
BeyondHello.jpg?fit=1200%2C800&ssl=1

4min24790

Jushi Holdings Inc. (OTCQX: JUSHF) is planning on buying Vireo Health’s (OTC:VREOF) Pennsylvania Medical Solutions, LLC as the company looks to strengthen its position in the state’s market. Jushi will pay Vireo $16.3 million in cash, a $3.8 million seller note, and assume a $17 million facility associated with a long-term lease obligation. The $37 million deal is expected to close by the end of August 20.

“This acquisition allows Jushi to expand its presence in one of the most attractive medical cannabis markets in the country,” said Jim Cacioppo, Chairman and Chief Executive Officer of Jushi. “Upon completion, Jushi will be able to provide high-quality, indoor flower and concentrates to our Pennsylvania patients who continue to experience constrained supply and high prices.  Furthermore, we will be well-positioned to support an increase in demand and maintain the ability to further scale up the facility if required.”

The acquisition operates a 90,000 sq. ft. facility with approximately 45,000 sq. ft. of high-quality, indoor cultivation when construction is complete. The property can also accommodate an additional 25,000 sq. ft. of indoor cultivation bringing the total to 70,000 sq. ft.

Pennsylvania has quickly shown its power in the cannabis industry with total sales of $524 million and 80 operational dispensaries. So far $215 million has been purchased by dispensaries from grower-processors and $309 million made by patients and caregivers at licensed dispensaries. Jushi says is has reaffirmed its revenue guidance for 2021 in the range of $200 and $250 million.

“This transaction secures Vireo’s capital position for the foreseeable future and will enable us to comfortably execute our fiscal year 2020 operating strategy and begin generating positive cash flow in the first half of next year without requiring any additional capital infusions,” said Founder & Chief Executive Officer, Kyle Kingsley, M.D.  Vireo said the money received from the sale will help it to increase scale in its core markets of New YorkMinnesotaMarylandArizona, and New Mexico. Vireo said that these projects are expected to significantly improve its near-term revenue and profitability outlook.

In addition to buying Pennsylvania Medical Solution, Jushi will have an option to buy  Pennsylvania Dispensary Solutions, a Pennsylvania medical marijuana dispensary permittee in the Commonwealth’s Northeast region.  PADS currently operates two medical marijuana dispensaries in Scranton and Bethlehem, with the right to operate one additional dispensary in the region. The option expires 18 months from the closing of the Agreement.

Financing

In order to help come up with the cash portion of the acquisition, Jushi announced it had received binding subscriptions totaling approximately $15.25 million for the issuance of 10% senior secured notes and warrants to acquire the subordinate voting share of which $12.35 million has been received. The company also said it received non-binding indications of interest for up to an additional $10 million of financing.  Jushi said it plans to use $15 million of the proceeds to fund the cash portion of the acquisition.

Jushi Chairman & CEO Jim Cacioppo subscribed for $1.5 million of the Notes with other insiders subscribing for $3.35 million of the Notes.


Debra BorchardtSeptember 17, 2019
Ilera.jpg?fit=960%2C960&ssl=1

3min20750

TerrAscend Corp. (CSE: TER)(OTCQX: TRSSF)  has closed on its previously announced acquisition of Pennsylvania-based Ilera Healthcare, one of five permitted vertically-integrated cannabis cultivator, processor, and dispensary operators in the state. The company also reaffirmed its 2019 guidance of revenue in excess of C$141 million, which includes a contribution from the Ilera transaction and pending disclosed transactions, as previously announced on August 22, 2019.

“As one of only 5 holders of Super Licenses in a limited license state with approximately 13 million people, Ilera is an ideal partner for TerrAscend to enter the Pennsylvania market with,” said Matthew Johnson, President of TerrAscend Corp., and TerrAscend USA, Inc. After the close of this acquisition, TerrAscend’s licensed cannabis footprint expands to four U.S. states, in addition to its global reach into Canada and Europe.

Greg Rochlin, CEO of Ilera, added, “By combining forces with TerrAscend, we see clear opportunities ahead for our stakeholders, employees, and patients. We look forward to accelerating the growth of Ilera’s brands and formulations by leveraging TerrAscend’s platform in other markets. I can’t wait to introduce our wholesale customers and patients to the California-born Valhalla and State Flower brands, as well as Haven Street, a leading premium Canadian brand.”

According to the company statement, Ilera currently operates a retail dispensary in Plymouth Meeting, PA, with plans to open two additional dispensary sites in the Philadelphia area within the next six months. The operations include a 67,000 square foot site for cultivation and processing in Waterfall, PA with planned expansion to over 120,000 square feet in 2020. In addition to selling its products in its own dispensary, Ilera distributes its dried flower, concentrates, tinctures, and topicals to over 60 dispensaries throughout Pennsylvania. Ilera’s current revenue run-rate is over US$43 million1, up from total sales in 2018 of less than US$8 million1.

Currently, the Pennsylvania medical marijuana program has more than 180,000 registered patients and 20,000 registered caregivers as of August 2019 and covers 23 qualifying medical conditions including anxiety disorders, cancer, and opioid use disorder.


Emerson BrownFebruary 12, 2018

6min37460

Pennsylvania seems to have forgotten its cannabis roots with the cautious approach the state is taking towards its medical marijuana program. William Penn, the man that American history states founded Pennsylvania, became a vital voice in Pennsylvania’s original outlook on cannabis.

Back in 1619, it was known as the “hemp state.” Yes, it was William Penn that gave way to the General Assembly passing the first law encouraging farmers to grow hemp and position the crop as a major commodity within the trade. It took over 300 years for cultivation to come back to the state.

On April 17, 2016, Governor Tom Wolf signed into law SB3, of the Pennsylvania Compassionate Medical Cannabis Act, which did not fully go into effect until May 17, 2016. The first medical marijuana dispensary in the state opened last month in Bethlehem, PA called Keystone Canna Remedies and Pittsburgh opened its first dispensary CY+ last week. Cure Pennsylvania is planned to open on March 7 in Lancaster County. A total of 12 companies will be able to grow and process medical marijuana with a vision of having a total of 25 in the near future. As of now, eight dispensaries have been approved and 10 growers/processors have begun operations.

“Each week, we are making great strides in expanding our network where patients will be able to get medical marijuana,” Governor Wolf said. “The approval of two more dispensaries is another positive step forward. Work continues to move patients one step closer to having medical marijuana as a tool to help with their medical condition.” According to Marijuana Business Daily estimates, the state’s dispensary sales could exceed $100 million annually a few years after the program launches.

Still, only 16,600 patients have registered to receive medical marijuana cards and 3,800 patients were certified by a physician. The physicians seem even less enthused. Take the process of registering qualified and actively licensed physicians for instinct, with a total of 57,670 active physicians statewide, to date, 701 have registered and of those, 355 have completed the training to become certified practitioners.

Now with Pennsylvania equipped to provide a service that not only helps the health of its residents but also creates a federal and state stream of taxable income that has yet to be matched by any other current commodity.

So the question that comes to mind, why are current northern American physicians so reluctant to jump into the medical lane of marijuana? Is there a cultural stigma holding these physicians back or is it a lack of education and marketing tools that can expose the future benefits of this sector of medicine? Will Pennsylvania have the same dilemma that New York had when it came to registering physicians or will the years ahead just show the solutions and strategies it took for Pennsylvania to overstep these current state structural and psychological barriers?

Back in 1683, Lancaster County in Pennsylvania was known to locals and most outsiders as the “hempest place to be” and with licenses being awarded for growers and processors to produce oil, pills, and tinctures. Counties like Lancaster seemed to have embraced those roots and is allowing out of state companies like Bay LLC to utilize and convert old 1970, brink and mortar stores like the Kmart on 890 Fruitville Pike in Manheim Township into 125,000 square feet of a modern-day dispensary.

I was thinking the process towards anything always has a beginning and an end. The thought of when and what to start and the notion of where and how to end it is a guarantee. So unlike many other states, Pennsylvania is a newcomer in this new booming cultural and economic class of cannabis, but with a commonly known and influential past.

Pennsylvania will slowly but surely makes its way into the headlines of the cannabis class going forward. I think its safe to say, that the state of Pennsylvania has a huge upside when it comes to the awareness and educational factors that help maximize the use and perception of cannabis within the framework of their local northeastern American economy. The medical sideline of Pennsylvania is leading the way back to making cannabis a common component in the wealth and health of its state.


Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.


About Us

The Green Market Report focuses on the financial news of the rapidly growing cannabis industry. Our target approach filters out the daily noise and does a deep dive into the financial, business and economic side of the cannabis industry. Our team is cultivating the industry’s critical news into one source and providing open source insights and data analysis


READ MORE



Recent Tweets

@GreenMarketRpt – 23 mins

Cresco Labs Revenue Falls From Fourth Quarter

@GreenMarketRpt – 3 hours

Psychedelics Takes A Seat On the World Stage

Back to Top

Choose Your News

Subscribe to the Green Market Report newsletter that gives you original content delivered straight to your inbox.

 Subscribe

We respect your privacy. See our privacy policy.